Surrozen (SRZN) Expected to Announce Earnings on Wednesday

Surrozen (NASDAQ:SRZN) will likely be posting its quarterly earnings results before the market opens on Wednesday, April 9th. Analysts expect Surrozen to post earnings of ($2.54) per share for the quarter.

Surrozen (NASDAQ:SRZN) last posted its quarterly earnings results on Monday, March 31st. The company reported ($9.10) EPS for the quarter, missing analysts’ consensus estimates of ($2.54) by ($6.56). The company had revenue of $0.66 million for the quarter. On average, analysts expect Surrozen to post $-8 EPS for the current fiscal year and $-11 EPS for the next fiscal year.

Surrozen Stock Performance

Surrozen stock opened at $10.99 on Monday. Surrozen has a fifty-two week low of $6.00 and a fifty-two week high of $18.17. The stock has a market cap of $35.72 million, a price-to-earnings ratio of -0.50 and a beta of 0.69. The stock’s 50 day simple moving average is $11.33 and its two-hundred day simple moving average is $11.09.

Insider Buying and Selling at Surrozen

In related news, major shareholder Group Gp Lp Column III purchased 1,034,482 shares of the business’s stock in a transaction that occurred on Wednesday, March 26th. The stock was purchased at an average price of $11.60 per share, with a total value of $11,999,991.20. Following the completion of the acquisition, the insider now owns 795,411 shares in the company, valued at $9,226,767.60. This trade represents a -432.71 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 43.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on SRZN. HC Wainwright reiterated a “buy” rating and set a $32.00 target price on shares of Surrozen in a research report on Wednesday, April 2nd. Guggenheim upgraded shares of Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 price target on the stock in a report on Friday, January 3rd.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.